ME
MDGL icon

McIlrath & Eck’s Madrigal Pharmaceuticals MDGL Stock Holding History

McIlrath & Eck’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.2K Hold
52
– – ﹤0.01% 718
2025
Q4 		$30.3K Hold
52
– – ﹤0.01% 438
2025
Q3 		$23.9K Hold
52
– – ﹤0.01% 469
2025
Q2 		$15.7K Hold
52
– – ﹤0.01% 523
2025
Q1 		$17.2K Hold
52
– – ﹤0.01% 503
2024
Q4 		$16K Hold
52
– – ﹤0.01% 526
2024
Q3 		$11K Hold
52
– – ﹤0.01% 611
2024
Q2 		$14.6K Hold
52
– – ﹤0.01% 524
2024
Q1 		$13.9K Hold
52
– – ﹤0.01% 549
2023
Q4 		$12K Hold
52
– – ﹤0.01% 522
2023
Q3 		$7.59K Hold
52
– – ﹤0.01% 583
2023
Q2 		$12K Hold
52
– – ﹤0.01% 534
2023
Q1 		$12.6K Hold
52
– – ﹤0.01% 506
2022
Q4 		$15.1K Hold
52
– – ﹤0.01% 457
2022
Q3 		$3K Hold
52
– – ﹤0.01% 719
2022
Q2 		$4K Hold
52
– – ﹤0.01% 650
2022
Q1 		$5K Hold
52
– – ﹤0.01% 638
2021
Q4 		$4K Hold
52
– – ﹤0.01% 662
2021
Q3 		$4K Hold
52
– – ﹤0.01% 653
2021
Q2 		$5K Buy
+52
New +$6.16K ﹤0.01% 623

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

McIlrath & Eck's MDGL Position: Q1 2026 in Review

McIlrath & Eck held its Madrigal Pharmaceuticals (MDGL) position steady in Q1 2026 at 52 shares worth $27.2K. The position accounts for ﹤0.01% of the portfolio, ranked #718.

McIlrath & Eck first reported a position in MDGL in Q2 2021 and has held it in 20 quarters since. The position peaked at $30.3K in Q4 2025. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • McIlrath & Eck held 52 shares of Madrigal Pharmaceuticals worth $27.2K as of Q1 2026.
  • McIlrath & Eck left its Madrigal Pharmaceuticals share count unchanged in Q1 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #718 holding.
  • McIlrath & Eck first reported a position in Madrigal Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • McIlrath & Eck's Madrigal Pharmaceuticals position peaked at $30.3K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.